VOLUNTARY ANNOUNCEMENTMEMORANDUM OF UNDERSTANDING - INVESTMENT COOPERATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.IVD Medical Holding Limited华检医疗控股有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 1931) VOLUNTARY ANNOUNCEMENT MEMORANDUM OF UNDERSTANDING – INVESTMENT COOPERATION This announcement is made by IVD Medical Holding Limited (the “Company” together with its subsidiaries collectively the “Group”) on a voluntary basis to provide the shareholders of the Company and potential investors with the latest information on recent business developments of the Group.The board (the “Board”) of directors (the “Director(s)”) of the Company is pleased to announce that on 29 May 2024 (after trading hours) the Company entered into a non-legally binding memorandum of understanding (the “MOU”) with a prospective partner in the PRC (the “Prospective Partner”) in relation to the investment cooperation (the “Proposed Cooperation”).The Company and the Prospective Partner are in the process of discussing possible ways of cooperation. The Company’s cooperation with the Prospective Partner includes but is not limited to business cooperation technical exchange equity investment capital increase and/or capital injection.EXCLUSIVITY PROVISIONS During twelve months from the effective date of the MOU the Prospective Partner shall not and shall cause its subsidiaries and their respective officers directors agents or representatives not to negotiate the purchase sale or cooperation matters relating to the MOU potential transactions and/ or equity of the Prospective Partner directly or indirectly with any party other than the Company and shall agree to immediately terminate any communication (if any) involving the purchase sale or cooperation matters relating to the MOU potential transactions and/or equity of the Prospective Partner with any party other than the Company. 1FORMAL AGREEMENT All parties to the MOU agree to make all reasonable efforts to negotiate the terms and conditions of a legally binding cooperation agreement (the “Formal Agreement”) to be entered into between the relevant parties to the Proposed Cooperation.The MOU shall become effective starting from the signature by both parties and ending on the following date whichever is the earliest: (i) when the parties replace the MOU with a formal sale and purchase agreement or a further agreement in relation to the subject matter of the MOU; or (ii) falling twelve months after the signing of the MOU unless otherwise agreed.BACKGROUND INFORMATION ON THE PROSPECTIVE PARTNER Established in 2011 the Prospective Partner is an in vitro diagnostics company with chemiluminescence technology and products as its core. The Prospective Partner has established a chemiluminescence technology platform based on alkaline phosphatase and the chemiluminescence reagent test function list includes sex hormones tumor markers thyroid functional hormones kidney function test bone metabolism myocardial markers hypertension liver fibrosis preoperative eight items and other sets.The Prospective Partner has many years of rich research and development experience and continuous research and development capabilities especially in the aspect of reagents which has a certain comparative advantage over their years of accumulation.To the best of the Directors’ knowledge information and belief having made all reasonable enquiries the Prospective Partner and its ultimate beneficial owners are independent third parties and are not connected with the Company and its connected persons (as defined in the RulesGoverning the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ListingRules”)).REASONS FOR AND BENEFITS OF THE MOU The Directors have been actively exploring suitable business opportunities by partnering with companies aiming to expand their revenue sources through extension of their existing business portfolio and engaging in new business activities with growth potential. In particular the Directors believe that the Proposed Cooperation will enable the Group to seize the business opportunities arising therefrom.The Directors are of the view that the Proposed Cooperation will offer opportunities to expand the revenue sources of the Group if it materializes and is in the interests of the Company and the shareholders as a whole. 2Pursuant to the Proposed Cooperation the Company will provide the Prospective Partner with subsequent operating funds. The wholly-owned subsidiaries of the Company shall sell the products of the Prospective Partner in accordance with the relevant requirements of the National Medical Products Administration which will eliminate various complicated steps including re-registration re-approval and adaption of products and bring the products of the Prospective Partner to the market by taking advantage of its own established sale channels.Upon completion of capital increase the Company shall leveraging on its funds and the advantages of self-owned brands and sales team support the research and development of biologic project products of the Prospective Partner so as to improve the products structure of the Company.The Company will utilize its own sales channels to promote the biologic project products of the Prospective Partner after considering market development trend of in vitro diagnostics (IVD) to strive to expand commercial channels promptly and achieve the Company’s performance growth.NATURE OF THE MOU The MOU does not constitute any legally binding commitment in respect of the relevant potential business cooperation save and except that each party agrees to be legally bound by certain clauses including exclusive period confidentiality governing laws and disputes resolution. The potential business cooperation between the Group and the Prospective Partner will only be finalized after the conclusion of negotiation and execution of the Formal Agreement between the relevant parties.GENERAL The Board wishes to emphasize that the Proposed Cooperation contemplated under the MOU may or may not proceed and that the parties have not entered into a legally binding agreement in relation to the transactions contemplated under the MOU as at the date of this announcement.If the transactions contemplated under the MOU materialize the Company will make further announcements as and when appropriate in accordance with the Listing Rules.Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.By order of the Board IVD Medical Holding Limited Ho Kuk Sing Chairman and Executive Director Hong Kong 29 May 2024 As at the date of this announcement the Board comprises four executive directors namely Mr. Ho Kuk Sing Mr. Lin Xianya Mr. Chan Siu Kei Ken and Mr. Law Kim Fai two non-executive directors namely Ms. Yao Haiyun and Mr. Liu Fei and three independent non-executive directors namely Mr. Zhong Renqian Dr. Leung Ka Sing and Mr. Wong Sze Lok. 3